Clinical Trial Update: 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 clinical trial evaluating 68Ga-RM26-RGD PET/CT imaging in GRPR- and αvβ3-positive tumors, including breast cancer and prostate cancer, and current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Breast Cancer
• Prostate Cancer

Drugs mentioned

• 68Ga-RM26-RGD (RM26-RGD radiotracer)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Breast Cancer, Prostate Cancer | EARLY_Phase 1 | Status: RECRUITING